# Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

> **NCT00245921** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 2000 (—)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg

## Key facts

- **NCT ID:** NCT00245921
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 2000 (—)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245921, "Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00245921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*